Clinical trial
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00040768 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00040768 |
|---|---|
| Title | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer |
| Official title | A Phase II Study Of PS-341 In Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 35 |
| Start date | Apr 1, 2002 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: